Skip Ribbon Commands
Skip to main content
Menu

AHCC Completed Studies

AHCC08​

Hepatocellular Carcinoma Registry in Asia (Clinicaltrials.gov Identifier: NCT03233360)​

​FundingIndustry (IQVIA)​
Period​17 Apr 2017 to 31 Dec 2020​
Status​​Completed recruitment of 2,533 patients in December 2019. Preliminary results presented at ASCO 2018, ILCA (2018), ASCO GI (2019) and APPLE (2019). Publication in progress
​Abstract​Previous studies contributed considerably to the knowledge of the HCC epidemiology, but there are significant limitations. These data do not represent real world data as these are from randomized controlled trials and case series from tertiary clinical centers. Real world data on the presentation, clinical trajectory and management of HCC in the Asia-Pacific must be prospectively collected on the ground in order to develop effective public health strategies and provide direction to the development of therapeutics. This investigator-initiated multi-site longitudinal cohort study includes newly diagnosed HCC patients between 2013 and 2019 in Asia-Pacific. Patients to be treated, managed and followed up according to local clinical practice. Data collection are aligned with patients’ routine visit. Patient-reported outcome (PRO) to be collected using paper questionnaires at each patients’ routine visit. Planned sample size is 2,500 patients from 9 countries.​
Outcome​Publication in progress​
​Contributing Principal Investigators and Centres

​Australia

Edmund Tse (Royal Adelaide Hospital), Simone Strasser (Royal Prince Alfred Hospital)

China

Li Lequn (Guangxi Medical University Cancer Center), Jiangtao Li (Second Affiliated Hospital Zhejiang University School of Medicine), Fan Jia (Zhongshan Hospital, Fudan University), Zhu Xu (Beijing Cancer Hospital), Yuxian Bai (Harbin Medical University Cancer Hospital), Qin Shu-Kui (Nanjing Bayi Hospital)

Hong Kong

Thomas Yau (Queen Mary Hospital)

Japan

Masatoshi Kudo (Kindai University Hospital), Junji Furuse (Kyorin University School of Medicine), Kazuaki Shimada (National Cancer Centre), Kiyoshi Hasegawa, (University of Tokyo), Nobuyuki Takemura (National Center of Global Health and Medicine)

New Zealand

Adam Bartlett (Auckland City Hospital)

Singapore

Pierce Chow (National Cancer Centre), Dan Yock Young (National University Hospital), Brian Goh (Singapore General Hospital)

South Korea

Hyun-Ki Yoon (Asan Medical Centre), Kim Yun-Hwan (Korea University Anam Hospital), Joon-Hyeok Lee (Samsung Medical Centre), Ho-Seong Han (Seoul National University Hospital), Yang Jin-Mo (St Vincents Hospital), Choi Jong-Young (St. Mary’s Hospital), Hee-Jung Wang (Ajou University Hospital), Do-Young Kim (Severance Hospital, Yonsei University College of Medicine)

Taiwan

Peng-Cheng Yuan (China Medical University Hospital), Yee Chao (Taipei Veterans General Hospital), Tsung-Hui Hu (KS-Chang Gung Memorial Hospital), Pin-Nan Cheng (National Cheng Kung University Hospital), Chien-Hung Chen (National Taiwan University Hospital)

Thailand

Rawisak Chanwat (National Cancer Institute), Supot Ninanong (Siriraj Hospital, Mahidol University)

​Protocol Chair

​Pierce Chow

pierce.chow.k.h@singhealth.com.sg

AHCC06​

Phase III Multi-Centre Open-Label Randomized Controlled Trial of Selective Internal Radiation Therapy (SIRT) Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma (SIRveNIB)
(Clinicaltrials.gov identifier: NCT01135056)

​FundingNMRC CSA 2010, NMRC IAF CAT 1 and Industry (Sirtex)​
Period​1 May 2010 to 28 Jul 2018​
Status​​Completed recruitment of 360 patients in July 2018. Results were presented at ASCO Annual Meeting (2017) on 4 June 2017, APPLE Meeting (Singapore) on 14-16 July 2017, Evidence Based Medicine Forum for Hepato-Biliary-Pancreatic Cancer (Hangzhou) on 4-6 Aug 2017 and ILCA conference (Seoul) on 15-17 Sep 2017 and published in Journal of Clinical Oncology (impact factor: 28.245) on 2 March 2018.
​Abstract​

The optimal therapeutic regime for locally advanced hepatocellular carcinoma (HCC) with and without vascular invasion remains unclear. This study evaluates the efficacy of Selective Internal Radiation Therapy using SIR-Spheres yttrium-90 microspheres (Y90) versus sorafenib in Asian Barcelona Clinic Liver Cancer (BCLC) stage B and C patients without extra-hepatic metastasis.

This investigator-initiated multi-center trial randomized eligible patients with locally advanced inoperable HCC to single injection of Y90 or sorafenib till progressive disease or unacceptable toxicity. The sample size, assuming type I error (two-sided) of 0.05 and power of 90% was 360 patients. Final analysis was planned at 266 reported deaths.

Outcome​

The trial found that patients with locally advanced HCC treated with Y90 have statistically significant better tumour-response-rates (TRR) and fewer serious adverse events (SAE) when compared with those treated with sorafenib. There were no statistically significant differences in overall survival between Y90 and sorafenib.

SIRT with Y90 is a significantly less toxic therapy with less serious adverse events such as diarrhoea, alopecia, hypertension, fatigue and hand-foot skin reactions. This is also similar to the findings in the SARAH (a similar trial conducted in France). Both trials showed that SIRT with Y90 is a less toxic therapy (for Asians and Europeans) and this is important for patients as SIRT imparts better quality of life. It also provided strong scientific support for the use of SIRT as a less toxic therapy. In the study, SIRT regressed the tumors of a significantly larger numbers of patients than sorafenib.

The scientific data from the trial established the safety and efficacy of loco-regional therapy with yttrium-90 in locally advanced HCC and gave clinicians the confidence to use SIRT in a larger number of patients. SIRT-Y90 became standard-of-care for locally advanced HCC patients in NCCS and elsewhere. To date, Singhealth has treated more than 500 HCC patients with Y90. The results were published in Liver Cancer (impact factor: 9.72) in April 2021.

Publications:

  1. Chew XH, Sultana R, Mathew EN, Ng DCE, Lo RHG, Toh HC, Tai D, Choo SP, Goh BKP, Yan SX, Loke KSH, Thang SP, Gogna A, Venkatanarasimha NK, Tong AKT, Moe FNN, Chua JSS, Ang RWT, Ong AD, Ng AWY, Hoang MTQ, Too CW, Thng CH, Chan WY, Kee W, Chan JHM, Irani F, Leong S, Lim KH, Wang MLC, Chow PKH. (2021) Real-World Data on Clinical Outcomes of Patients with Liver Cancer: A Prospective Validation of the National Cancer Centre Singapore Consensus Guidelines for the Management of Hepatocellular Carcinoma. Liver Cancer. https://doi.org/10.1159/000514400
  2. Pierce K.H. Chow, Mihir Gandhi, Say-Beng Tan, et al. (2018) SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients with Hepatocellular Carcinoma. J. Clin. Oncol., https://doi.org/10.1200/JCO.2017.76.0892.
  3. Gebski V, Gibbs E, Gandhi M, Chatellier G, Dinut A, Pereira H, Chow PK, Vilgrain V (2017) VESPRO: An Individual Patient Data Prospective Meta-Analysis of Selective Internal Radiation Therapy Versus Sorafenib for Advanced, Locally Advanced, or Recurrent Hepatocellular Carcinoma of the SARAH and SIRveNIB Trials. JMIR Res. Protoc. 6(2):17. https://doi.org/1010.2196/resprot.7016.
  4. Chow, P.K., Gandhi, M., and Gebski, V. (2017). The Sirvenib and Sarah Trials and the Role of Sir-Spheres(R) Y-90 Resin Microspheres in the Management of Hepatocellular Carcinoma. Future Oncol.,13:2213-16. https://doi.org/10.2217/fon-2017-0395.
  5. Gandhi M, Choo SP, Thng CH, Tan SB, Low AS, Cheow PC, Goh AS, Tay KH, Lo RH, Goh BK, Wong JS, Ng DC, Soo KC, Liew WM, Chow PK (2016) Single administration of Selective Internal Radiation Therapy versus continuous treatment with sorafeNIB in locally advanced hepatocellular carcinoma (SIRveNIB): study protocol for a phase iii randomized controlled trial. BMC Cancer 16(1):856. https://doi.org/10.1186/s12885-016-2868-y.
​Contributing Principal Investigators and Centres

Brunei

Kenneth Kok (The Brunei Cancer Centre)

Indonesia

L.A Lesmana (Cipto Mangunkusumo Hospital, University of Indonesia), Tjakra Wibawa Manuaba (Sanglah General Hospital, Denpasar)

Malaysia

Aloysius Raj (Penang Adventist Hospital), Nik Azim Bin Nik Abdullah (Sarawak General Hospital), Yoong Boon Koon (University Malaya Medical Center)

Mongolia

Ariunaa Khasbazar (National Cancer Center of Mongolia)

Myanmar

Khin Maung Win (Yangon GI & Liver Centre)

New Zealand

Adam Bartlett (Auckland City Hospital)

Philippines

Rolley Lobo (Davao Doctors Hospital), Catherine Teh (Makati Medical Center), Janus Ong (The Medical City), Ian Cua (St Luke’s Medical Center)

Singapore

Kenneth Mak (Khoo Teck Puat Hospital), David Tai (National Cancer Centre), Dan Yock Young (National University Hospital), Cheow Peng Chung (Singapore General Hospital)

South Korea

Hyun-Ki Yoon (Asan Medical Center), Yun-Hwan Kim (Korea University Anam Hospital), Ho-Seong Han (Seoul National University Bundang Hospital) Si-Hyun Bae (Seoul St Mary’s Hospital), Jong Yun Won (Severance Hospital, Yonsei University), Jin-Mo Yang (St Vincent’s Hospital)

Taiwan

Chien-Fu Hung (Chang Gung Memorial Hospital), Chao-Long Chen (Chang Gung Memorial Hospital, Kaohsiung), Cheng-Yuan Peng (China Medical University Hospital), Po-Chin Liang (National Taiwan University Hospital), Rheun-Chuan Lee (Taipei Veterans General Hospital)

Thailand

Chanisa Chotipanich (Chulabhorn Hospital)

​Protocol Chair

​Pierce Chow

pierce.chow.k.h@singhealth.com.sg

AHCC05 Phase I/II Study of SIR-Spheres plus Sorafenib (Chemo-Radiotherapy) as First Line Treatment in Patients with Non-Resectable Primary Hepatocellular Carcinoma (Clinicaltrials.gov identifier: NCT00712790)
FundingNMRC and Industry (Sirtex)
Period1 Jun 2008 to 30 Jun 2011
StatusCompleted recruitment of 35 patients in June 2009. Published in PLoS ONE (impact factor: 3.240) on 10 March 2014.
Abstract

The safety and tolerability of sequential radioembolization-sorafenib therapy is unknown. An open-label, single arm, investigator-initiated Phase II study (NCT0071279) was conducted at four Asia-Pacific centers to evaluate the safety and efficacy of sequential radioembolization-sorafenib in patients with hepatocellular carcinoma (HCC) not amenable to curative therapies.

Sorafenib was initiated 14 days post-radioembolization with yttrium-90 (90Y) resin microspheres given as a single procedure. The primary endpoints were safety and tolerability and best overall response rate (ORR) using RECIST v1.0. Secondary endpoints included: disease control rate (complete [CR] plus partial responses [PR] and stable disease [SD]) and overall survival (OS).

Outcome

Twenty-nine patients with Barcelona Clinic Liver Cancer (BCLC) stage B (38%) or C (62%) HCC received a median of 3.0 GBq (interquartile range, 1.0) 90Y-microspheres followed by sorafenib (median dose/day, 600.0 mg; median duration, 4.1 months). Twenty-eight patients experienced $1 toxicity; 15 (52%) grade $3. Best ORR was 25%, including 2 (7%) CR and 5 (18%) PR, and 15 (54%) SD. Disease control was 100% and 65% in BCLC stage B and C, respectively. Two patients (7%) had sufficient response to enable radical therapy. Median survivals for BCLC stage B and C were 20.3 and 8.6 months, respectively. This study shows the potential efficacy and manageable toxicity of sequential radioembolization-sorafenib.

Publication:

  1. Chow, P. K., Poon, D. Y., Khin, M. W., Singh, H., Han, H. S., Goh, A. S., Choo, S. P., Lai, H. K., Lo, R. H., Tay, K. H., Lim, T. G., Gandhi, M., Tan, S. B., and Soo, K. C. (2014) Multicenter phase II study of sequential radioembolization-sorafenib therapy for inoperable hepatocellular carcinoma. PLoS One, 9:90909. https://doi.org/10.1371/journal.pone.0090909. PMID: 24614178
Contributing Principal Investigators and Centres

Singapore

Pierce Chow (Singapore General Hospital), Anthony Goh (Singapore General Hospital), Alexander Chung (Singapore General Hospital), Soo Khee Chee (National Cancer Centre), Lai Hee Kit (Singapore General Hospital), Tay Kiang Hiong (Singapore General Hospital), Richard Lo Hoau Gong (Singapore General Hospital), Donald Poon Yee Hee (National Cancer Centre), Choo Su Pin (National Cancer Centre)

South Korea

Han Ho Seong (Seoul National University Hospital)

Malaysia

Harjit Singh (Selayang Hospital)

Myanmar

Khin Maung Win (Yangon GI & Liver Centre)

Vietnam

Hoang Hoa Hai (Choray Hospital)

Protocol Chair

Pierce Chow

pierce.chow.k.h@singhealth.com.sg

AHCC04 Phase II Dose Escalating Trial of Intra-Tumoral BrachySil in Unresectable Hepatocellular Carcinoma
(Clinicaltrials.gov identifier: NCT00247260)
FundingpSiVida Limited and pSiOncology Private Limited
PeriodOct 2005 to Feb 2007
StatusCompleted. Results Published in International Journal of Radiation Oncology *Biology* Physics Vol. 67, Issue 3, 1 March 2007; 786-792.
Abstract

Brachytherapy is a recent technique used in the treatment of tumours and involves the use of radioactive sources brought into close contact with the target tissues. One of the principal benefits of brachytherapy is that high radiation doses can be localised within the tumour with the consequence of minimal side effects. 32P is a radionuclide ideal for brachytherapy as it has high energy beta emitting properties, typically a maximum tissue range of about 8 mm and a half-life of 14.3 days. 32P BioSiliconTM is an active implantable medical device encapsulating 32P within the internal microcrystalline structure of highly pure inert silicon and acts as a sealed source for the provision of 32 phosphorous.

Tumours targeted with 32P BioSiliconTM are hypothesized to show a reduction in volume with a low incidence of side effects associated with the treatment. Prolongation of survival and improved quality of life would be favourable outcomes of the investigational product.

Patients will be enrolled sequentially into the three groups, starting with Group 1 which will investigate the lower radioactivity level and then progress to a higher radioactivity level in Group 2 and then Group 3. The approval to enroll patients into the next group will be assessed and determined by a Data Monitoring Board. All patients will be followed up to 52 weeks from the start date of primary implantations.

Patients will receive intratumoural implantations of 32P BioSiliconTM under imaging guidance and local anaesthesia by designated interventional radiologists, using the SIMPL needle or conventional needles depending on the size and location of the tumour as assessed by the designated interventional radiologists. There are only a designated number of sites that will perform the implantation procedure although there are multiple sites recruiting and following up with patients.

  • Tumour assessment, tumour calculation and measurement will be performed by an independent radiologist. CT scans from all participating sites will be sent in DICOM format to the designated radiologist for assessment.
  • Safety assessment and grading of CTCAE will be performed by the same investigator for that same patient throughout the entire study period. There will be an interim analysis when all patients complete 24 weeks evaluating the safety profile and target tumour response of the patients.
  • 32P BioSiliconTM will be prepared by designated personnel licensed to handle radioactive products and all radioactive waste will be handed and managed as per the institution's guidelines and in compliance with local regulatory requirements.
Outcome

Implantations were successfully carried out in 8 patients (13–74 MBq, mean 40 MBq per tumor) awake and under local anesthesia. Six of the 8 patients reported 19 adverse events, but no serious events were attributable to the study device. Changes in hematology and clinical chemistry were similarly minimal and reflected progressive underlying hepatic disease. All targeted tumors were responding at 12 weeks, with complete response (100% regression) in three lesions. At the end of the study, there were two complete responses, two partial responses, three stable diseases, and one progressive disease.

Percutaneous implantation of this novel 32P brachytherapy device into hepatocellular carcinoma is safe and well tolerated. A significant degree of antitumor efficacy was demonstrated at this low dose that warrants further investigation.

Publication:

  1. Goh, A. S., Chung, A. Y., Lo, R. H., Lau, T. N., Yu, S. W., Chng, M., Satchithanantham, S., Loong, S. L., Ng, D. C., Lim, B. C., Connor, S., and Chow, P. K. (2007) A novel approach to brachytherapy in hepatocellular carcinoma using a phosphorous32 (32P) brachytherapy delivery device--a first-in-man study. Int. J. Radiat. Oncol. Biol. Phys., 67:786-92. PMID: 17141975
Contributing Principal Investigators and Centres

Singapore

Pierce Chow (Singapore General Hospital), Anthony Goh (Singapore General Hospital), Richard Guan (Mt Elizabeth Hospital), Foo Kian Fong (National Cancer Centre), Susan Loong (National Cancer Centre), Liau Kui Hin (Tan Tock Seng Hospital)

Malaysia

Harjit Singh (Selayang Hospital)

Vietnam

Hoang Hoa Hai (Choray Hospital)

Protocol Chair

Pierce Chow

pierce.chow.k.h@singhealth.com.sg

AHCC03 Randomised Trial of Adjuvant Intra-Arterial Radio-Active Iodine after Curative Resection of Hepatocellular Carcinoma
(Clinicaltrials.gov identifier: NCT00027768)
FundingNMRC
PeriodJun 2001 to Mar 2007
StatusCompleted recruitment of 103 patients in March 2007. Published in World Journal of Surgery on 6 March 2013.
AbstractRadioactive iodine may be effective in reducing the rate of recurrence of liver cancer after surgery to remove the tumor. It is not yet known if radioactive iodine is more effective than no further treatment after surgery. This randomized phase III trial to determine the effectiveness of radioactive iodine in treating patients who have undergone surgery for liver cancer.
Outcome

Publication:

  1. Chung, A. Y., Ooi, L. L., Machin, D., Tan, S. B., Goh, B. K., Wong, J. S., Chen, Y. M., Li, P. C., Gandhi, M., Thng, C. H., Yu, S. W., Tan, B. S., Lo, R. H., Htoo, A. M., Tay, K. H., Sundram, F. X., Goh, A. S., Chew, S. P., Liau, K. H., Chow, P. K., Tan, Y. M., Cheow, P. C., Ho, C. K., and Soo, K. C. (2013) Adjuvant hepatic intra-arterial iodine-131-lipiodol following curative resection of hepatocellular carcinoma: a prospective randomized trial. World J. Surg., 37:1356-61. PMID: 23463394
Contributing Principal Investigators and Centres

Singapore

Pierce Chow (Singapore General Hospital), Lucien Ooi (National Cancer Centre), Tay Khoon Hean (Changi General Hospital), Chew Soo Ping (Tan Tock Seng Hospital)

Protocol Chair

Pierce Chow

pierce.chow.k.h@singhealth.com.sg

AHCC02 Randomized Double Blind Trial of Megestrol Acetate Versus Placebo for the Treatment of Inoperable Hepatocellular Carcinoma
(Clinicaltrials.gov identifier: NCT00041275)
FundingPivotal Clinical Trials Grant from SingHealth
PeriodMar 2002 to Jun 2007
StatusCompleted recruitment of 204 patients in June 2007. Results published in British Journal of Cancer on 23 August 2011.
Abstract

Hepatocellular carcinoma (HCC) is the third leading cause of cancer deaths worldwide. We tested megestrol acetate (MA) against placebo in the treatment of advanced HCC.

From 2002 through 2007, this randomised double-blind trial enrolled 204 patients with treatment-naive advanced HCC (Eastern Cooperative Oncology Group (ECOG) performance rating of 0-3) from specialist care centres in six Asia-Pacific nations. Patients received placebo or MA (320 mg day1). End points were overall survival (OS) and quality of life.

Outcome

An adverse but not statistically significant difference in OS was found for MA vs placebo: median values 1.88 and 2.14 months, respectively (hazard ratio (HR)¼1.25, 95% CI¼0.92–1.71, P¼0.16). However, OS was similar among patients of good functional status (Child-Pugh A and ECOG 0, 1 or 2) (44.3%) in both treatment groups, with the adverse effect of MA confined to those of poor status. Megestrol acetate patients had a worse global health status (not statistically significant) but reduced levels of appetite loss and nausea/ vomiting. Megestrol acetate has no role in prolonging OS in advanced treatment-naive HCC. Overall survival with placebo differed markedly from that in similar trials conducted elsewhere, suggesting therapeutic outcomes may be strongly dependent on ECOG status and Child-Pugh score.

Publication:

  1. Chow, P. K., Machin, D., Chen, Y., Zhang, X., Win, K. M., Hoang, H. H., Nguyen, B. D., Jin, M. Y., Lobo, R., Findlay, M., Lim, C. H., Tan, S. B., Gandhi, M., and Soo, K. C. (2011) Randomised double-blind trial of megestrol acetate vs placebo in treatment-naive advanced hepatocellular carcinoma. Br. J. Cancer, 105:945-52.
Contributing Principal Investigators and Centres

Singapore

Soo Khee Chee (National Cancer Centre), Pierce Chow (Singapore General Hospital)

Myanmar

Khin Maung Win (Yangon GI & Liver Centre)

New Zealand

M Findlay (Cancer Trials New Zealand)

Philippines

Rolley Rey Lobo (Davao Doctors’ Hospital)

South Korea

Yang Jin-Mo (St. Vincents Hospital)

Vietnam

Hoang Hoa Hai (Choray Hospital), Nguyen Ba Duc (National Cancer Institute K Hospital)

Protocol Chair

Pierce Chow

pierce.chow.k.h@singhealth.com.sg

AHCC01Randomised Trial of Tamoxifen Versus Placebo for the Treatment of Inoperable Hepatocellular Carcinoma
(Clinicaltrials.gov identifier: NCT00003424)
FundingNMRC
Period4 Apr 1997 to 8 Jun 2000
StatusCompleted recruitment of 324 patients in June 2000. Results published in Hepatology on 20 August 2002.
AbstractHepatocellular carcinoma (HCC) is endemic in the Asia-Pacific region. Surgery is the only treatment modality that significantly prolongs survival but almost 90% of patients are inoperable at diagnosis. Tamoxifen (TMX) is believed to retard HCC positive for estrogen receptor (ER), but previous phase III trials in inoperable HCC have been conflicting and inconclusive. Most HCCs are also ER negative. Tamoxifen at higher doses, is however, known to retard HCC through ER-independent mechanisms. The objective of the project was to assess the role of high-dose TMX versus placebo (p) in the treatment of inoperable HCC with survival as the primary endpoint and quality of life (QoL) as the secondary end-point. The methodology used was a prospective double-blind controlled randomized trial with TMX 120mg/day in the study arm and P in the control arm and an intermediate dose arm of TMX 60 mg/day to assess possible dose response. Randomisation was done through the data center in Singapore. Trial safety and quality controlled was ensured via site audits and an independent Data Monitoring Committee. QoL of patients was assessed using the EORTC QLQ-C30 questionnaire.
Outcome

329 patients were recruited. Reported adverse drug reaction was 3% and 8 patients were lost to follow-up. The 3-month survival rates for P, TMX60 and TMX 120 were 44%, 41% and 35% respectively with significant trend difference in crude survival rates across the 3 treatment regimens (p=0.011). There is a significantly higher risk of death in TMX120 as compared with P (HR:1.39;95% CI of HR: 1.07 to 1.81). In conclusion, TMX does not prolong survival in inoperable HCC and has a negative impact with increasing dose. Changed international clinical practice with respect to the treatment of inoperable HCC. The practice of treating such patients with tamoxifen was found to be detrimental.

Publication:

  1. Chow, P. K., Tai, B. C., Tan, C. K., Machin, D., Win, K. M., Johnson, P. J., and Soo, K. C. (2002) High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: A multicenter randomized controlled trial. Hepatology, 36:1221-26. (DOI: 10.1053/jhep.200236824) PMID: 12395333
Contributing Principal Investigators and Centres

Australia

Jonathan Cebon (Austin Health)

Hong Kong

Phillip Johnson (Prince of Wales Hospital, Chinese University of Hong Kong)

Indonesia

T Manuaba (Sanglah General Hospital)

Malaysia

A Haron (Hospital Universiti Kebangsaan)

Myanmar

Khin Maung Win (Yangon GI & Liver Centre)

New Zealand

M Findlay (Cancer Trials New Zealand)

Singapore

Soo Khee Chee (National Cancer Centre), Tan Chee Kiat (Singapore General Hospital)

South Korea

Si-Hyun Bae (St. Mary’s Hospital)

Thailand

Thiravud Khuhaprema (National Cancer Institute)

Protocol Chair

Pierce Chow

pierce.chow.k.h@singhealth.com.sg